NCT06305286View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions
Diabetes Mellitus
Interventions
DRUG

AT-1501

AT-1501 is a monoclonal antibody for Injection is a humanized immunoglobulin G1 (IgG1) kappa monoclonal anti-CD40L antibody that blocks CD40L binding to its receptor, CD40.

Trial Locations (1)

60637

RECRUITING

University of Chicago, Chicago

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

collaborator

Cure Alliance

UNKNOWN

lead

University of Chicago

OTHER